News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Taking lenient stance, NICE backs neuroblastoma drug Body makes special case due to rarity of the disease
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.